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Background: The public reporting of health outcomes has become one of the most popular topics and is
accepted as a quality improvement method in the healthcare field. However, little research has been conducted on
the transparency mechanism, and results are mixed with regard to the evaluation of the effect of public reporting
on quality improvement. The objectives of this trial are to investigate the transparency mechanism and to evaluate
the effect of public reporting on prescription at the level of individual participants.
Methods/Design: This study involves a cluster randomized controlled trial conducted in 20 primary-care facilities
(clusters). Eligible clusters are those facilities with excellent hospital information systems and that have agreed to
participate in the trial. The 20 clusters are matched into 10 pairs according to Technique for Order Preference by
Similarity to Ideal Solution score. As the unit of randomization, each pair of facilities is assigned at random to a
control or an intervention group through coin flipping. Prescribed ranking information is publicly reported in the
intervention group. The public materials include the posters of individuals and of facilities, the ranking lists of general
practitioners, and brochures of patients, which are updated monthly. The intervention began on 13th November 2013
and lasted for one year. Specifically, participants are surveyed at five points in time (baseline, quarterly following the
intervention) through questionnaires, interviews, and observations. These participants include an average of 600
patients, 300 general practitioners, 15 directors, and 6 health bureau administrators. The primary outcomes are the
transparency mechanism model and the changes in medicine-prescribe. Subsequently, the modifications in the
transparency mechanism constructs are evaluated. The outcomes are measured at the individual participant level,
and the professional who analyzes the data is blind to the randomization status.
Discussion: This study protocol outlines a design that aims to examine the transparency mechanism and to evaluate
the effect of public reporting on prescription. The research design is significant in the field of public policy.
Furthermore, this study intends to fill the gap of the investigation of the transparency mechanism and the evaluation
of public reporting on prescription.
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Transparency as a popular policy issue
Transparency has become one of the most popular
topics and is a widespread normative doctrine for govern-
ance conduct [1,2]. The value of transparency has rarely
been questioned now. Many governments and organiza-
tions, such as the US and the European Union, have de-
signed public systems to reduce financial, health, and safety
field risks, as well as to improve public services [3,4].
In the field of healthcare, the public reporting of the
performance data obtained from providers has been
widely used to improve the quality of care. Almost all
US states have implemented numerous reporting programs
for hospitals, and the Center for Medicare and Medicaid
Services has initiated public disclosure programs for hospi-
tals, manages care plans, nursing homes, and home health
agencies [5]. In South Korea, a national insurance review
agency has been releasing information regarding antibiotics
use rates among healthcare organizations publicly since
2006 [6].
In 2009, the Chinese government emphasized the im-
portance of increasing transparent regulation in the med-
ical field, such as on the rational use of antibiotics and on
prescription comments. This policy is highly significant in
promoting transparency in medicine use, which is a most
urgent necessity. Many local governments have attempted
to develop such policies; however, few research results
have been published thus far.
Poor sound evidence for the medical public
Many studies that evaluate the effect of the public
reporting of performance data on healthcare quality im-
provement report mixed results [7,8]. Hannan et al. [9]
and Schneider and Epstein [10] of public reporting sys-
tems in the US have reduced cardiac surgery mortality
and have motivated hospitals and health plans to im-
prove the quality of care provided. However, critics have
noted that the link of public reporting to improved out-
comes lacks evidence. Jang [11] reported that the repeated
release of cesarean section rates to the public did not sig-
nificantly lower these rates. Furthermore, Bundorf [12]
assessed a reporting program for Medicare health main-
tenance organizations and stated that public reporting
does not significantly and positively affect quality. More-
over, few studies have examined the relationship between
the public reporting of prescribed ranking information
(PRPRI) and the rational use of medicines (RUM) [13].
In view of the methodology, few transparency studies
have conducted cluster randomized controlled trials. A
comparison group was set in Bundorf ’s [12] study, but
a new policy was implemented during the study period.
Jang’s [11] study also generated a control group, but
this study involved the analysis of secondary data. Fur-
thermore, confounding was not matched. Hibbard [14]applied a quasi-experimental method and set a control
group, but this group was not randomly selected. There-
fore, either a high-quality experimental or a cluster ran-
domized controlled trial design must be developed to
determine whether the public reporting of information in-
fluences quality improvement.
Few related theories for and empirical research on the
transparency mechanism
Berwick, James, and Coye [15] indicated that public report-
ing can improve performance in two ways (selection and
change). These aspects are interconnected by the motiv-
ation of a provider to maintain or to increase market share.
Fung [16] proposed the transparency action cycle. Accord-
ing to the theory, “Effective public transparency systems
trigger a virtuous chain of action and reaction. First, con-
sumers, voters or other information users react to new
facts by changing their perceptions and behavior. Second,
manufacturers, political candidates or other information
disclosers change their perceptions and behavior in re-
sponse to users’ actions in order to improve their competi-
tive advantage”. Both Berwick and Fung reported that
public reporting should be advocated to improve the
healthcare quality of providers by presenting information,
selection, and change activities.
Little empirical research has been conducted on the
transparency mechanism. Sherman et al. [17] evaluated the
perceptions of surgeons at hospital-level and individual-
level public reporting and identified specific barriers to
their acceptance of this reporting. This study enhances
understanding regarding the concerns of surgeons with re-
gard to public reporting and promotes its widespread im-
plementation. Hibbard, Stockard, and Tusler [18] indicated
that patients who can perceive public reporting and the
mechanism by which it can affect quality improvement ac-
curately are more likely to be concerned with reputation
than with market share.
Research questions and significance
The Institute of Medicine defines healthcare transparency
as the concept of making healthcare available to the public
in a reliable and understandable manner. It mainly focuses
on the reporting of information and processes [19]. In the
current study, we emphasize only public reporting in the
field of medicine use. Our research questions include the
follows: “Is Fung’s theory applicable in the field of medi-
cine use?” How does it work? If it does not work, why?
This research aims to fill a gap in the literature on the
investigation of the transparency mechanism and the
evaluation of public reporting on prescription by applying
a cluster randomized controlled trial design. It intends to
contribute significantly to both theory development and
practical guidance. First, tools are developed to measure
the key constructs of the transparency mechanism and to
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based on Fung’s theory in the field of medicine use. Sec-
ond, a controlled randomized cluster trial is applied to
evaluate the effect of PRPRI on RUM and to provide a ref-
erence to researchers and policy makers with respect to
the effect of public reporting based on sound evidence.
Objectives
The primary objective is to investigate the transparency
mechanism in the field of medicine use based on Fung’s
transparency action cycle and to test the robustness of
this mechanism using five times’ panel data. The second-
ary objective is to evaluate the effect of PRPRI on pre-
scription, namely, whether PRPRI can promote the RUM
of a general practitioner (GP). All objectives are consid-
ered at the level of individual participants.
The main hypotheses in this study contain the follow-
ing points: (1) PRPRI can promote RUM; (2) PRPRI can
affect information accessibility, perception, stress level,
and the behavior intention of information users (includ-
ing GPs, directors of primary-care facilities, and patients
at these facilities, as well as their families); (3) the original
information disclosers may in turn perceive the changes
in the users and respond accordingly (these disclosers in-
clude research team and the local health bureau). Based
on Fung’s transparency action cycle, all of these hypoth-
eses comprise the framework of our research, which is il-
lustrated in Figure 1.
Methods
Study design
This study employed a cluster randomized controlled
trial that was designed to comply with the guidelines of
the Consolidated Standards of Reporting Trials (CON-









Figure 1 Study framework of the transparency action cycle.(see Additional file 1). The reasons for adopting cluster
randomization include the following: (1) it prevents con-
tamination because GPs and patients who come from
one primary-care facility may either share or uninten-
tionally transfer intervention effects from one group to
another; (2) clustering at the level of the primary-care fa-
cility conveniently implements intervention and improves
administrative efficiency. The clusters are the primary-
care facilities in Q City, which served more than one
billion outpatients and emergent patients, and assisted
30,000 inpatients on average in 2013.
Primary-care facilities were matched in pairs according
to Technique for Order Preference by Similarity to Ideal
Solution (TOPSIS) score. This score was generated as
per nine indicators, including the service population, ap-
proval beds, number of physicians, number of outpatients,
number of inpatients, revenues, payment for performance,
and the time and number of RUM training courses. First,
we calculated the TOPSIS score of all 22 primary-care fa-
cilities in Q City. Given the limited number of researchers
and financial resources, the two facilities with the lowest
TOPSIS score, were removed. Second, we arranged the
20 facilities in the order of descending TOPSIS score and
marked them with numbers 1 to number 20. Thus, we
can sequence the numbers for the 20 facilities. Third, we
matched two consecutive primary-care facilities into
one pair. For example, the facility labeled number 1 was
matched with that set as number 2. A total of 10
matched pairs of facilities were generated. Finally, one
facility from each matched pair was randomly allocated
by coin flipping to the intervention group while the
other was assigned to the control group.
In the intervention group, the medicine-prescribing
ranking information that ranks the personnel and the fa-












Du et al. BMC Public Health  (2015) 15:277 Page 4 of 9their families. In addition, patients were also provided
with brochures that contain information regarding RUM
and medicine-prescribing ranking information. The con-
trol group does not enforce such public reporting activ-
ities. The intervention lasted for one year, starting from
November 2013. Survey data were collected at five points
in time (baseline and quarterly after intervention) using
questionnaires, interviews, and observation (Figure 2).
Setting and participants
This study was conducted in Q City, which is a typical
city in central Hubei Province. This city has 1,030,000
inhabitants and covers approximately 2004 km2. As per
eligibility criteria for cluster level, the facility should be
located in Q City; it must agree to participate in the trial;
and it must have an excellent hospital information sys-
tem (HIS).
The individual-level participants in this research in-
cluded information users and disclosers. All GPs who
work in a participating facility and have the license to
prescribe medicine during our intervention period were
eligible for the study. Patients were included only if they
met the following criteria: they should have noted drug
reimbursement, the price of the medicine, or other22 facilitie
Pairs matched acco
TOPSIS sco
Inclusion of 10 pairs
Intervention group (N=10)
Baseline survey (GPs, directors
Intervention
Regular surveys after intervention (GP
Randomly allocated to interventi
Figure 2 Design of the matched-pair cluster randomized controlled trmedical information; they must be able to understand
our intervention materials and communicate with the
investigators; and those in the intervention group should
also have paid attention to the publicly reported pre-
scribed ranking information. The families of the patients
could be eligible if either the young or the elderly pa-
tients could not answer the questionnaires. The criteria
for the eligibility of the directors of the facilities and of
health bureau administrators for the study are as follows:
they must be active participants, and they must be re-
sponsible for public reporting.
Sample size
The research team completely enumerated all eligible
GPs, and an average of 300 GPs were surveyed at each
time point. We conducted purposive sampling to deter-
mine the interviewees. Moreover, sample sizes typically
rely on the gold standard of “saturation”, which is the
point at which no new information or theme is observed
in the data [21]. It estimates the interviews of 15 direc-
tors and 6 administrators in advance at each time point.
This study adopted convenience sampling to investigate
the patients. The sample size of patients is calculated as
follows. First, we calculate the number of patients in ans
rding to 
re
 of facilities 
Control group (N=10)
, administrators, patients) 
s, directors, administrators, patients)  
on group and control group
ial.
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Stockard, and Tusler [18], 63% of the patients in the
intervention group and 40% of the patients in the con-
trol group patients are aware of public reporting in the
medical healthcare field. We assumed that the probabil-
ity estimates of the outcome indicators were p1 = 0.63
and p2 = 0.4 in our intervention and control groups, re-
spectively. Given an alpha value of 5% and a beta value
of 20%, we calculated n1 = 113 for each group based on
Formula (1) [22]. Second, we computed the required
sample size (nc) for a cluster randomized controlled trial
based on individually randomized trial sample size using
Formula (2), which was developed by Hemming et al.
[23]. In our study, the number of clusters (k) was fixed
at 10 per arm, and we assumed that the intra-cluster
correlation coefficient (ρ) is 0.05. Therefore, we calcu-
lated 247 per arm as the required sample size for our
cluster randomized trials. Supposing that the valid re-
sponse rate is 95% based on our previous survey experi-
ence, we enlarged the sample size to 260 patients for
each group. Finally, 26 patients from each facility should





2  arcsin ﬃﬃﬃﬃﬃp1p − arcsin ﬃﬃﬃﬃﬃp2pð Þ2 ð1Þ
nc ¼ n1k 1−ρð Þk−n1ρ ð2Þ
Randomization and blinding
The randomization sequence was set by coin flipping.
For example, flip a coin and determines heads of the
number one facility and then the number two facility is
tails. We flipped the coin until all 20 facilities are marked
as heads or tails. Therefore, the randomization sequence
was established by flipping the coin 10 times prior to the
beginning of program implementation. The facilities
marked as heads were allocated to one group as interven-
tion group and those marked with tails to another. The
primary-care facilities were the unit of allocation, and the
research team alone was aware of the allocation of all of
the clusters. Blinding the research team was impossible
because it plans and implements the intervention activ-
ities. Furthermore, participants were told only that they
are participating in a trial, but they were not aware of their
allocation. The professional who analyzed the data was
blinded to the randomization status of the primary-care
facilities until statistical analysis is completed.
Recruitment
The primary-care facilities (clusters) are recruited via the
local health bureau. The health bureau introduced the
objectives and design of the cluster randomized controlledtrial to these facilities and invited them to participate. All
eligible participants (directors, administrators, patients,
and all GPs in each facility) were recruited through word-
of-mouth from members of the project team prior to each
survey period. The participants were informed of the pur-
pose of the trial and that the questionnaire data were con-
fidential and would be used only for research purposes.
They also received the information sheet and were given
sufficient time to read it, to consider any implications, and
to raise any questions to the investigators prior to deciding
to participate.Intervention
The intervention aimed to publicly report the ranking of
antibiotic prescription percentage, injection prescription
percentage, and average drug cost per prescription at
both facility and GP levels. The public materials included
the posters of individual GPs and of facilities, the ranking
lists of GPs, and the brochures of patients. We calculated
the public materials based on the prescription data of the
outpatients in the previous month and updated the public
materials monthly. The ranking poster of the facilities
pertained to cluster-level intervention. The poster and
ranking list of the GPs and the brochures of patients
pertained to individual participant-level intervention.
The intervention was a multi-level intervention, but it
targeted individual-level variables.Intervention materials
Ranking list of GPs
The ranking list contained the names of GPs and de-
partments, antibiotic prescription percentage, injection
prescription percentage, the average drug cost per pre-
scription, the rankings in departments, and the star
rankings among the 10 facilities. The ranking in depart-
ments was based on a comprehensive indicator calculated
according to antibiotic prescription percentage, injection
prescription percentage, and the average drug cost per
prescription as determined by TOPSIS. The ranking re-
sults were presented in ascending order. The star rankings
among the 10 facilities denoted the ranks of all GPs in the
same departments of 10 facilities. The calculation method
of these star rankings was similar to that for the rankings
in departments. One-third of the highly ranked GPs were
ranked with three stars, one-third of those ranked in the
middle were ranked with two stars, and the remaining
GPs were ranked with only one star. The higher the rank
result, the more stars were accorded. The calculation
method and rankings were interpreted at the bottom of
the ranking list, in which high ranks and many stars repre-
sented the use of high-quality medicine. The ranking lists
of GPs were printed in black on A4-size paper and were
distributed to them monthly.
Du et al. BMC Public Health  (2015) 15:277 Page 6 of 9Bulletin board and the poster
The poster included the ranking posters of the GPs and
facilities. Many information users are not medical pro-
fessionals; hence, the posters were simplified based on
the ranking list of the GPs. The ranking poster of the
GPs included only the names of the GPs and depart-
ments, the rankings in departments, and the star rank-
ings among the 10 facilities. The ranking posters of
facilities included the names of the facilities and the
rankings among the 10 facilities. The rankings of the fa-
cilities was based on a comprehensive indicator that was
calculated based on the antibiotic prescription percent-
age, the injection prescription percentage, and the aver-
age drug cost per prescription at the facility level as
determined by TOPSIS. The ranking results were sorted
in ascending order. Both types of posters provided the
interpretation of the calculation method and rankings at
the bottom. The ranking posters of the GPs and facilities
were color-printed on A3-size paper and were posted on
the provided bulletin board measuring 0.8 m × 1.2 m.
Brochures of patients
The brochures of patients included the contents of both
the facilities’ poster and the ranking list of GPs, as well
as relevant knowledge regarding the concept of RUM,
the harmful effect of irrational medicine use, and the sig-
nificance of RUM promotion. All brochures were printed
in color on A4-size paper.
Intervention procedure
Preparation of intervention materials
First, outpatient prescription data from the 5th to the
10th of each month were retrieved from the HIS through
the local health bureau starting from October 2013. Sec-
ond, the RUM indicators for each GP and facility were cal-
culated and then ranked based on TOPSIS. The RUM
indicators used to monitor the prescription behavior in
our intervention were adapted from those of the WHO/
INRUM (International Network for the Rational Use of
Drugs), which were widely used [24-26]. To ensure the
accuracy of the calculation results, the ranking out-
comes were cross-checked by two researchers. Third,
the intervention materials were printed by a professional
printing company.
Publicly reported intervention materials
The investigator posted the ranking posters and dissem-
inated the ranking list to 10 intervention facilities and
to each GP from the 10th to the 15th of each month.
Simultaneously, our researchers distributed the bro-
chures to the outpatients, inpatients, and their families.
The rest of the brochures were placed in the publicity
column, which was accessible to the patients. All of the
intervention materials were provided to each facilitydirector monthly in the intervention group. Throughout
the entire intervention process, 120 copies of ranking
posters of GPs, 120 ranking posters of the facilities,
1,800 ranking lists of GPs, and 1,000 of patient bro-
chures were distributed.
Guaranteed measures of intervention
The health bureau of Q City issued documents to con-
firm that the posters should be protected and that they
must not be destroyed or covered. The research team
patrolled intervention facilities irregularly to verify the
completeness and cleanliness of the posters. They also
replaced the damaged posters.
Data collection
Questionnaire survey
To develop the questionnaires for the transparency mech-
anism, we acquired references from previous studies.
Items were adapted from other instruments and from ex-
pert opinions. Based on the literature review, a large pool
of items was generated, and disputed items were removed
as per several rounds of discussions among experts. Prior
to collecting data in full, we conducted a pilot study to test
the reliability and validity of the new measure and either
removed or adjusted the items with low reliability. The
questionnaire consisted of four constructs: information
accessibility, perception, stress, and behavior intention
for both GPs and patients. All items were measured
with a five-point Likert scale. The survey also included
demographic variables, such as age, sex, income, and
education levels.
This study conducted five investigations on GPs (base-
line, 3, 6, 9, and 12 months after intervention) and three
investigations on patients (baseline, 3 and 12 months
after intervention) for both the intervention and the con-
trol groups. Panel data from the two groups were used to
test the robustness of the mechanism with the structural
equation model (SEM).
Interview with key informants
We designed an interview outline and conducted four
semi-structured interviews during the intervention period.
The directors of primary-care facilities and health bureau
administrators were our key interview objects because
they communicated with and coordinated the research
team and the facilities to ensure the smooth implementa-
tion of the intervention. We also interviewed key GPs that
prescribed more than 200 prescriptions per month. The
interview focused mainly on the transparency mechanism
and its function conditions. Meanwhile, the general char-
acteristics of the facilities, RUM promotion activities, such
as commenting on prescriptions, RUM training, and the
highest limit of antibiotic and injection prescription per-
centage, are also involved. The interview data were used
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using grounded theory method.
Observation survey
The research team observed the attitudes and behavior of
directors and key GPs toward the intervention. The obser-
vation diary recorded the events (what), times (when),
places (where), processes (how), and reasons (why). These
records were as detailed as possible and were used to in-
terpret the transparency mechanism.
Outpatient prescription data
The prescription data of all of the outpatients from the 20
facilities during the period of October 2013 to October
2014 were collected monthly. These data include patient
IDs and medicine information, such as medicine name,
dosage, and price. They were used to calculate the RUM
indicators for public materials and to evaluate the effect of
intervention.
Quality assurance
The questionnaire survey was distributed according to
standard operational protocol, and the investigators were
trained accordingly. A face-to-face survey was conducted
to emphasize timely explanations to respondents. We also
incorporated mutual verification questions into the ques-
tionnaire. If the chosen items were contradictory, then the
respondents were required to answer the questionnaire
again. The double data entry method was used to input
paper-based questionnaires. Inconsistencies were investi-
gated by reviewing the paper-based version.
Notes were taken during then interviews. The researchers
also recorded the interviews in full after obtaining the con-
sent of the interviewees. Two researchers who were blind
to the intervention group independently encoded the inter-
view data. Disagreements were resolved via discussions with
the other researchers.
Prior to the start of the investigations, the health bureau
issued documents to highlight the importance of the study
and to inform facilities and GPs to cooperate in respond-
ing to the survey. Additionally, patients and GPs were
given small gifts, such as umbrellas, cups, and toothpaste,
to improve cooperation and questionnaire response rate.
Outcome measures and statistical analysis
The primary outcomes are the transparency mechanism
model and the change in five RUM indicators before
and after intervention. The secondary outcomes are the
modifications in transparency mechanism constructs, in-
cluding information accessibility, information percep-
tion, stress level, and behavior intention. Outcomes were
measured at the individual participant level.
The multi-method design included both qualitative
and quantitative methods, such as generalized estimatingequations (GEE) and grounded theory. Quantitative ana-
lysis was conducted using STATA (version 12.0). Further-
more, the software NVivo 8.0 was employed to manage
and index transcriptions into a coding system. The spe-
cific analysis indicators and the statistical analysis are
listed in Table 1.
Ethics
This study was approved by the Ethics Committee of
Tongji Medical College, Huazhong University of Science
and Technology (NO: IORG 0003571). It was also per-
mitted by the local health bureau. Patient names and
other confidential data included in outpatient prescrip-
tion information were secured according to medical con-
fidentiality rules.
Discussions
This paper describes the protocol of a matched-pair
cluster randomized controlled trial that aims to explore
and test the robustness of the transparency mechanism,
as well as to evaluate the effect of public reporting on pre-
scription in primary-care facilities. Although the transpar-
ency mechanism and effect have been examined and
assessed in previous studies [7,17,18], our trial has some
unique features.
First, the large-scale, one-year trial investigates both
information users and disclosures quarterly through
questionnaires, interviews, and observations methods.
Each investigation surveys 300 GPs and 600 patients. In
addition, 700,000 prescriptions are retrieved during our
study. Moreover, the approaches of qualitative and quanti-
tative methods were mixed. For example, SEM was used
to establish and to test the robustness of the transparency
mechanism with five times’ panel data. Grounded theory
was applied to analyze the interview materials as an im-
portant supplemental evidence for transparency mechan-
ism research. Meanwhile, the GEE and DID method was
employed to study the outpatient prescription data re-
trieved from HIS and evaluate the effect of intervention.
Second, another distinguishing feature of the design is its
focus on primary-care facilities. Previous studies usually
research the public reporting issues in hospitals [9-13].
Primary-care facilities are increasingly important worldwide
as gatekeepers of good health [27]. Elucidating the mechan-
ism and effect of transparency in primary-care facilities can
not only improve healthcare services for 1.4 billion Chinese
but also provides references for other countries.
The study in Q City provides strong evidence for the
examination of transparency mechanism and for the
evaluation of the effect of public reporting on prescription.
Furthermore, this study fills the gap of the investigation of
transparency mechanism and the evaluation of PRPRI on
prescription. Thus, it can contribute significantly to both
theory development and practice. With respect to
Table 1 Outcomes and statistical analysis of the study
Outcome measures Statistical analysis
Outcomes Indicators or constructs Description
RUM Antibiotic prescription
percentage
Calculated by dividing the number of
antibiotic prescriptions to patients by
the total number of prescriptions in a
certain period of time. This value is then
multiplied by 100.
Propensity Score Matching (PSM): This
method reduces the influence of bias and
confounding variables and reasonably




Calculated by dividing the number of
injection prescriptions to patients by the
total number of prescriptions in a certain
period of time. This value is then
multiplied by 100.
Difference-in-difference (DID): The
variations in an index of the two groups
before and after intervention are calculated
to reflect the net effect of intervention. The
differences lie in the cluster-level summaries
of the two groups.
Average drug cost per
prescription
Calculated by dividing the total cost of
all drugs prescribed by the number of
prescriptions in a certain period of time.
Generalized estimating equations (GEE):
For multivariate outcome analyses, we
used GEE to assess the effect of PRPRI
intervention with repeated measures at the
individual participant level. For continuous
dependent variables, we used the GEE
model with a normal apply and an identity
link function. For dichotomous dependent
variables, we employ the GEE model with
a binomial distribution and a logit link
function.
Prescription percentage
of drugs listed in the
essential drug list or
formulary
Calculated by dividing the number of
prescribed products listed on the
essential drugs list or local formulary (or
of those that are equivalent to drugs on
the list) by the total number of products
prescribed in a certain period of time.





Calculated through dividing the number
of patient prescriptions during the time
a duplicate or more antibiotics were
prescribed by the total number of





Information accessibility Accessibility score Factor analysis: This method evaluates the
reliability and validity of the questionnaire.
Information perception Perception score Structural equation modeling (SEM): This
technique builds the inner link of each
construct of the transparent mechanism and
tests the robustness of the mechanism by
applying the questionnaire data from two
groups four times.
Stress level Stress score







The code of information accessibility,
perception, behavior, and other related
influence factors.
Grounded theory: The qualitative data
were analyzed through a thematic
framework. Codes were then developed
based on the viewpoints that were derived
from these data.
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measurements of the key constructs and variables of the
transparency mechanism. It also establishes relationships
among the constructs in the field of medicine use. In
terms of practical guidance, this research enhances under-
standing regarding the concerns of stakeholders and the
behavioral change in public reporting. Hence, this study
significantly facilitates RUM and promotes the widespread
implementation of public reporting.
Nonetheless, our design also has some limitations.
First, the grouping process according to TOPSIS score
considers only the key influence factors of RUM and
does not take into account the prescription factor at the
baseline levels of the 20 primary-care facilities. There-
fore, the DID analysis method was used in the study to
remedy the deficiency of the design [28]. Second, theHawthorne effect may be induced during our study, es-
pecially during the interviews. We will improve the com-
munication between the researchers and the participants
to reduce this effect as much as possible [29]. Finally,
the intervention lasts for only one year, but the observa-
tion of some effects may require long-term follow-up
surveys. Therefore, we may have underestimated the de-
tected intervention effect.
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Additional file 1: CONSORT 2010 Cluster RCT Checklist.
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